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AbstrACt
background This study reports how parents and young 
people who had an experience of febrile neutropenia (FN) 
improved the design of a trial to inform the management 
of this condition. Five parents, a young person who had 
completed treatment and three clinician-researchers 
contributed.
Methods The group was formed after an invitation 
on social media and met via video conference. Many 
participants were from an existing childhood-cancer 
parent-involvement group. The initial questions asked 
during discussion were about the importance of the 
topic, the views on the need for a trial, which important 
outcomes should be measured and the practical aspects 
which would make it easier or more dificult for people 
to take part in it. The conversation occurred for an entire 
afternoon, was audio and video recorded, transcribed, 
analysed and checked by those involved. The ifth parent 
added to this via email.
results The group altered the trial structure by proposing 
randomising of each child to one of the two management 
methods through the whole of their anti-cancer treatment, 
rather than randomising the study sites or the child at each 
visit. They felt that even if people declined taking part in 
the study in the irst weeks of diagnosis, their views might 
change and they should be allowed to consent later. They 
also proposed methods of collecting important patient and 
family data, enriching the medical information gained in 
the study. Active follow-up, negotiated for each individual 
family, was also suggested.
Conclusion Trials for improving the management of 
FN in children and young people who are undergoing 
anti-cancer treatments should consider individual-patient 
randomisation, collection of ‘quality of life’ and ‘experience 
of care’ aspects using digital and paper-based methods, 
engage families in shared decision-making about 
management options and ensure adequate supportive 
information is available and accessible to all patients 
regardless of background, geographical location or age.
IntroduCtIon
In high-income countries, the treatment 
of malignancies in childhood is associated 
with 5-year survival rates in excess of 80%.1 
This is possible through the use of inten-
sive, toxicity-inducing regimens, where 
one-third of deaths in this group are the 
result of complications of therapy rather 
than directly due to the disease.2 3 The cancer 
treatment often produces acute complica-
tions requiring unplanned hospitalisation, 
disruption, distress and strain for the young 
persons and their families.4 One such compli-
cation is the co-occurrence of fever in the 
presence of neutropenia; this combination 
heralds a possible overwhelming infection 
and is considered a medical emergency.5 
The absolute risk of death or requirement of 
intensive care in such episodes is low, approx-
imately 3%.6 The challenge for families 
What is already known on this topic?
 Ź Febrile neutropenia (FN) is a common complication 
of childhood cancer therapy and is disruptive and 
resource intensive.
 Ź Trials for reduction in intensity of treatment for 
fFN have previously been challenging for parents to 
accept.
 Ź Parent/patient and public involvement in trials has 
improved study designs, research comprehension 
and engagement materials.
What this study hopes to add?
 Ź Parent/patient and public involvement in a proposed 
trial for reducing antibiotic treatment for febrile neu-
tropenia (FN) led to changes in fundamental aspects 
of trial design.
 Ź Proposed outcome assessments were enhanced by 
experts with experience who described the burden 
of treatment and trial procedures for FN.
 Ź Video conferencing for parent/patient and public 
was effective despite the participants not knowing 
each other well.
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and healthcare professionals is to effectively treat each 
episode, with minimum exposure to antibiotics and 
disruption of family life.
Research into episodes of febrile neutropenia(FN), and 
subsequent clinical practice guidelines have emphasised 
the need to treat promptly, assess the risk of each episode 
and treat with antibiotics chosen to address individual and 
local resistance patterns.5 The methods of risk assessment 
and discontinuation of antibiotic therapy are, however, 
precautionary and conservative, treating two-thirds of 
patients with broad spectrum antibiotics unnecessarily.7 
Studies have shown that biomarkers of infection/inflam-
mation seem to predict the risk of serious infection and 
its resolution, but have not been used to guide manage-
ment.8 Further refinement of the approach to FN has 
been identified as a research priority.5
In analogous situations with critically ill or immuno-
compromised hosts, such as adult or neonatal intensive 
care units, traditional management is similar to that of 
FN, with the prompt use of antibiotics and their discon-
tinuation when infection has been excluded. Procalci-
tonin-led guidelines have been shown to reduce exposure 
to antibiotics and potentially improve mortality rates.9 10
The need to improve the management of FN led to the 
development of a research proposal to use procalcitonin, 
which is tested on a blood sample, to assist antibiotic deci-
sion-making during episodes of FN. It was felt that the 
decision on how to conduct such a study (which outcomes 
are important to measure, how to measure them and 
the possible barriers and solutions for a trial) was best 
taken with the engagement of clinicians, academics, and 
parents and young people who had had direct experience 
of anti-cancer treatment in childhood. Previous work has 
shown how such involvement led to improved research 
focus, better interview questions and enhanced the skills 
of children and young people undertaking such work.11
This paper reports the findings of a patient/public 
involvement (PPI) group which researchers, parents and 
young people convened to design a study to investigate 
procalcitonin-assisted decision-making in the manage-
ment of FN in children undergoing anti-cancer therapy.
Method
A request was made on social media for parents and 
young people who had had experience of childhood 
cancer therapy to consider taking part in a group to 
discuss the proposed trial. Volunteers were recruited and 
after initially attempting a face-to-ace meeting to promote 
inclusiveness and working together, a video conference 
platform (Zoom) was used to overcome geographical 
barriers. The researchers, all clinical doctors with addi-
tional academic roles, met in one location and the public 
contributors took part from their own homes. One 
participant could not get the integrated audio working; 
so he joined the conversation via telephone and mute 
video. The discussion lasted 2 hours and 15 min.
The session was structured to introduce FN, the 
existing evidence for the proposed intervention and the 
rationale for a randomised feasibility study (see box 1 
for the initial plan). The PPI group had knowledge of 
clinical studies, including trials, in children and young 
people with cancer. The discussion followed a series of 
questions about the experience of FN, its management, 
the perceived challenges with current approaches and 
how the study could be best organised to meet these.
The session was video and audio recorded. The entire 
meeting was transcribed after audio immersion and the 
content thematically studied. Elements of the conver-
sation related specifically to the design and conduct of 
the study were developed into themes and sub-themes. 
Elements related to the management of FN were exam-
ined within a framework derived from the themes devel-
oped in a relevant PhD thesis.12 Following the meeting, 
a summary was shared and agreed, and the full report 
from which this paper is derived was reviewed by the PPI 
group.
The costs of the group were small; transport costs and 
light refreshments only for the researchers and a small 
fee for the video conferencing platform. The platform 
and the technologies were already owned by the partic-
ipants. The participants volunteered their time, in line 
with their voluntary involvement in similar charitable 
activities, and did not receive payment.
As this was a patient/public engagement group, no 
ethical review was required. This is consistent with the 
INVOLVE definition of public involvement in research as 
‘research being carried out ‘with’ or ‘by’ members of the 
public rather than ‘to’, ‘about’ or ‘for’ them’,13 Despite 
the lack of a formal requirement for research ethics 
committee oversight, an ethical approach to such work 
is necessary. Such an approach has been described,14 and 
the key elements of a fair choice to partake in the work, 
appropriate training and support to understand the 
questions asked, making sure access was as equitable as 
possible and providing recognition for the work were all 
considered in this project.
results
Participants
Four volunteer parents were part of the UK-based Paedi-
atric Oncology Reference Team (PORT) organisation 
which consists of parents of children and young people 
box 1 original trial design
 Ź Site-randomised trial (randomising by hospital) using cluster or 
step-wedge approach.
 Ź Use of single "quality of life" questionnaire at discharge.
 Ź Contact with patient for trial purposes to occur only while in-patient 
– not after discharge.
 Ź Antibiotic decision-making on procalcitonin measurements and 
clinical judgement without family involvement.
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who have had experience of childhood cancer. Each was 
the mother of a child who had undergone cancer treat-
ment, two with leukaemia and two with neuroblastoma. 
The children of three of these four parents had died of 
their disease. A patient who had had leukaemia as a teen-
ager also took part in the group, though unrelated to the 
other participants. Of the three researchers, two were 
higher specialist trainees in paediatric oncology, and 
one a consultant, who was the only male member in this 
group. Each member of the group had prior experience 
with research in children’s cancer beyond participation. 
The discussions involved descriptions of past experiences 
of admissions with fever and neutropenia. The experi-
ences were from 2006–2017. During that time period, 
there has been a move to effect some reduction in the 
length of stay and marginally more consistency between 
centres in the UK.15 Additional comments were added by 
a fifth PORT parent via email following the video confer-
ence.
study-speciic themes
Information regarding the undertaking and conduct 
of the study was described under three major themes; 
‘importance’, ‘how PPI changes researchers’ views’ and 
‘practical and ethical’. The theme of ‘importance’ was 
formed by concepts of ‘medical consequence’, ‘psycho-
logical consequence’, ‘impact’, ‘unpredictability’ and 
‘frequency of FN’. (See figure 1).
Importance: The group members unanimously agreed 
that the management of episodes of FN was important 
because of its unpredictability, frequency and medical, 
psychological and social (‘impact’) consequences. 
They described particularly how variation in care across 
different hospitals was a source of concern to them and 
consistency would be a positive by-product of under-
taking a trial:
we’ve got the 20-odd centres and pretty much ev-
erybody follows the same protocols [for anti-cancer 
treatment]… and I think it would be really reassur-
ing for families if the POSCUs [Paediatric Oncology 
Shared Care Units] you know if we knew that every-
body was doing the same thing [P1]
 ‘How PPI changes researchers’ views’ describes the impact 
of this work: how PPI is important in modifying the 
initial, genuinely held presumptions and beliefs about 
the best ways to conduct such a trial for families and chil-
dren and young people. These beliefs were drawn from 
the trial development group, the group of clinicians and 
researchers involved in designing the trial, which has 
over a century of experience in working with children’s 
cancer in a variety of units and countries and specific 
expertise in studying supportive care in this group 
of patients. The impact of the group is seen in in the 
following aspects:
Allocation: The initial suggestion was for group rando-
misation, assigned arms to by clinical unit rather than 
by individual patients. However, the PPI input strongly 
steered towards individual randomisation, but with 
each individual receiving the same arm of management 
throughout the whole trial.
with paediatric oncology unlike many other things… 
everybody is on a trial… everybody… I mean… 
<snip>… I think everyone just expects that their 
treatment may be a bit different than everyone 
else’s… [P2]
once you’re randomised rather than each time com-
ing in and by randomised each time, you’re better 
off having ‘this family is procalcitonin, this family is 
not’ [P1]
Figure 1 Interaction of themes and sub-themes.
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Outcome assessment: The group members felt direct 
measures of patient experience would be important, 
more than ‘quality of life’ checklists. They suggested 
offering a daily experience journal of some form (paper 
or electronic, ‘app’ based), and believed this would 
supplement and enrich the medical data collected, such 
as admission duration, antibiotic duration and infective 
organisms.
capturing that idea of burden beyond the hospi-
tal-based stuff and things that matter to the family, 
[P3]
They described how it would be important to measure 
the extra resources required because of FN admissions. 
The word ‘impact’ was felt to capture this rather than 
‘costs’.
impact, because it’s not just about extra costs, I mean 
if you’re having to call in grandparents and you’re 
having to call in favours left right and centre,<snip> 
I mean how many times can you ask the next door 
neighbours to collect your kids from school [P1]
Active safety netting: The researchers initially felt 
that the standard approach after the discharge of respon-
sibilities passed to the family to ‘return if unwell’ would be 
safe and acceptable, but the PPI group thought an active 
approach to safety-netting was necessary, but should be 
individually negotiated.
I think it needs to be more than just you phone up 
the hospital if you have any concerns. It should be ei-
ther somebody coming around or phoning you and 
saying ‘Do you have any concerns, do you have any 
concerns at all’ and actually if you say yes …… giving 
you the option of coming back or having somebody 
over [P4]
Gaining consent: The researchers proposed, as with 
usual practice, the study would be offered once to fami-
lies when the clinician believed it appropriate. The group 
members, with their experience of studies and informa-
tion being exchanged, thought it would be fair to allow 
people to decline early on but have the opportunity to 
join the study if they changed their mind as their treat-
ment journey progressed. They also floated the idea of 
families approaching clinicians to join rather than being 
invited.
I don’t think I even knew what febrile neutropenia 
was though, at the time when we were first giving our 
consent to all the other things? I think that’s some-
thing that possibly comes with… further on… down 
the line… even a week or 2 weeks after you’ve given 
all those other consents. Because actually, the other 
consents are almost live-saving things… whereas this 
is a real choice… and I think that batching it in with 
those initial forms of consents is almost taking away 
your flexibility of trying to consider it whether you 
want to do it or not [P4]
You might also get people saying ‘No’ right at the 
beginning, if it’s something they don’t have to agree 
with, and then subsequently further on during their 
treatment when they can really see the how much of 
a headache that this can be… [giggles]
- Do you think it’s OK then to offer it twice? If some-
body says no the first time? [R1]
Yes – I think I do [P4]
Because it’s not like chemo A vs chemo B, it’s not … 
it’s not crucial like… you can opt in whenever you 
want [P2]
The theme of ‘practical and ethical considerations’ 
included the ethical aspects of; consent, randomisa-
tion, delays introduced by undergoing the trial, equity 
and equality, and the sharing of trial data. The practical 
aspects described outcome collection, safety netting, and 
ensuring the veracity of information collected in the trial.
Randomisation was considered a fair and ethical 
approach when in clinical equipoise. Along with this, a 
later discovery of one arm proving better than the other 
was not considered unethical; however if being on the 
study disadvantaged everyone (for example, if the treat-
ment would be delayed while forms were completed) 
then it would not have been supported. A design which 
was accessible for the diversity of social, cultural and 
economic backgrounds of potential participants was 
essential. Confirmation of the scientific validity of the 
proposal and clinical equipoise was important to the PPI 
group. Prior systematic reviews with meta-analysis were 
felt to be a very comprehensive answer to this question.
Two of the three researchers have a strong interest in 
individual participant data meta-analysis. A question was 
asked about data sharing in this context and the PPI were 
very enthusiastic about being involved.
Definitely share. I think the thing with paediatric 
oncology is that we do so many international trials 
together, because thankfully it is rare, but ultimately 
I think that… [snip] we’re here ultimately to try to 
make things better for kids of the future and if that’s 
part of it, and it is with these meta-analysis, then defi-
nitely. [P1]
The group members were concerned about study 
governance, for example ensuring the veracity of infor-
mation collected during the study.
are they [study groups] actually going to tell you the 
truth? [P2]
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The members were keen to know if there would be 
some way of determining if the data collected were 
truthful and accurate; this seems to speak of a greater 
public awareness being required of the nature of health 
research governance within the country generally.
An offer of expression of interest in continuing to 
engage with the study governance was enthusiasti-
cally met with by the participants. One of the group 
members has joined the funding application as a co-ap-
plicant, has helped develop the grant application and will 
be involved in qualitative data collection and analysis as 
a co-investigator.
Febrile neutropenia themes
Conversations in these discussions were mapped to 
the framework proposed by Morgan, developed to 
understand the decision-making processes involved in 
managing episodes of FN.12 The overarching concepts 
she described were the quest for certainty, attaining 
mutual trust and the potential for realised discretion. 
These were all strongly endorsed in analysis of the group 
discussion.
The quest for certainty involves balancing the uncer-
tainty of outcome of each episode of FN including an 
appreciation of probability, the use of protocols and 
guidelines to manage the risk and acknowledging the 
adverse elements of hospitalisation. The use of protective 
isolation, where the child and family are kept in a single 
room to avoid contracting infections from other hospi-
talised children, and source isolation, where the child is 
kept in a single room to prevent his/her infection from 
spreading to others, was viewed particularly negatively.
It was his cupboard—[child] called it his cupboard 
[P3]
Mutual trust had been a challenge, with the group 
describing individual healthcare practitioners in whom 
they did not place trust and the reciprocal of this, along 
with the negation of parental concerns.
the first time that I thought it was that they were tak-
ing too much precaution and I would have much pre-
ferred him to be at home taking tablets and things… 
monitored every so often… whereas the second time 
I think he needed more than what he was getting… 
and I think we were right both times actually [P4]
The ideal management of an episode of FN was one 
where safety was assured, hospitalisation was minimised, 
decisions discussed with families and support provided 
at home as desired by the family: the potential for real-
ised discretion. The group readily acknowledged that 
decisions would need to be based on a range of factors, 
including home-to-hospital distance and the varia-
bility between parents and families in self-expressed 
confidence:
my sort of worry is that… the responsibility is even 
more on the parent as well… on top of like running 
the house… and its that sense of responsibility as 
well… like they’re monitoring their child and being 
responsible for it… and like if something did happen 
would they feel guilty about it or not? [P5]
Exploring how the professionals were thinking about 
the episode, in terms of the likelihood of adverse 
outcomes and their considerations, was a strength in a 
shared decision-making approach which had been absent 
in many prior experiences.
I think it would be really helpful, [imitates Dr speak-
ing]… we think its’ like this [left] or we think it’s 
like this [right]… and then chatting… and …… You 
know where you are coming from and where there is 
a difference and you know talking about … [P2]
seem to recall being in negotiations… situations 
where… ringing [PTC] consultants saying ‘This is 
our situation… can you speak to them and and so 
on…’ [P4]
relections of clinical academics
The group discussions encouraged the three researchers 
to reflect on their previous approaches to FN and PPI 
in other studies. The more experienced researchers had 
participated in PPI before, but always on a face-to-face 
basis. The video conferencing allowed for a more diverse 
group of individuals to undertake the work, with the 
researchers in the same room on one screen facilitating. 
The makeshift arrangement of audio for one participant 
through phone served to reduce hierarchies, with collab-
orative suggestions and problem-solving forming an 
early ‘win’ for the group. This method worked well with 
the age and technological skills of this group, but may 
be less successful if a group with fewer technology skills 
or younger age were involved. The protocol changes 
suggested by the group were unexpected, as was the 
emphasis on the emotional burden of physical isolation. 
The researchers understood from this experience the 
value of listening to expert parents and young adults, and 
considering video or tele-conferencing to allow a greater 
number and range of people to take part in PPI events.
dIsCussIon
The engagement of a group of parents and an ex-patient 
who had experience of cancer in children and young 
people, with researchers developing a study to improve 
the management of FN, led to changes in the proposed 
design of the trial and brought out a deeper under-
standing of the potential concerns of participants. The 
wider discussions about the nature of the experience of 
an episode of FN were congruent with prior work in the 
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field,12 pointing particularly to actively involving parents 
and young people in sharing decisions about care.
The PPI altered how the trial would be structured, 
the randomisation of each child to one of the two 
management methods through the whole of his/her anti-
cancer treatment, rather than randomising the study sites 
or the child at each visit (see box 2 for specific changes). 
The suggestion of providing multiple opportunities to be 
involved in the study was welcome and congruent with 
the description of an emerging expertise and empower-
ment of people through the childhood cancer journey.16 
They discussed practical methods of collecting data, 
which went beyond simple admission statistics and ques-
tionnaires, to enrich the information gained in the study. 
Active follow-up, with healthcare-initiated contact with 
the family but negotiated with each individual family, 
had not been originally considered by the researchers. 
The discussion also shed light on the experiences of 
the people involved in treatments of episodes of FN, with 
the ideal treatment being an individualised, negotiated 
approach with clear and safe guidance used consistently 
across all centres.
The expertise and prior relationships of the group 
members in similar situations may have enhanced the easy 
flow of ideas and conversations in this event. All members 
knew at least one other participant through in-person 
interactions in similar group settings or clinical interac-
tions. Ice-breaking activities were extremely brief as there 
was little ice to be broken. None of the participants were 
paid for their time in undertaking this work. Though the 
INVOLVE guidelines suggest involvement should come 
with reimbursement, the group undertook the work as 
charity related to childhood cancer treatment, research 
and support and saw this as an extension of their other 
activities. Future PPI work with similar groups of people 
will benefit from considering holding group conversations 
via a video conferencing platform. The ready availability 
of web-cams and front-facing cameras on phones, tablet 
and laptops and the common use of video conversations 
at work and home mean these were acceptable methods 
for discussions with this group. There are limitations 
with this approach. It requires a familiarity and access to 
such equipment and access to a relatively stable internet 
connection. This may exclude particularly young people 
from disadvantaged backgrounds from PPI. It may also 
be very difficult to use for working with younger chil-
dren or older family members, perhaps great-grandpar-
ents, who are unfamiliar with video conferencing. If the 
approach is used, it may be beneficial to have a ‘test run’ 
prior to the meeting to allow any technical challenges to 
be met; we would suggest a sensible way forward would be 
allocating a period of time for ‘drop in’ connections to 
confirm everything is working well. A backup, as simple 
as a telephone line, is also very helpful.
We used social media (Twitter) to recruit the partic-
ipants; as all the researchers had prior experience of 
working with PORT, and ‘tagged’ them into a post, 
this may be considered a mixture of open and direct 
messaging. This type of use has been fairly widely under-
taken previously17 and has advantages and disadvan-
tages. It carries little direct risk as it doesn’t ask people 
to engage in a discussion in a forum (such as Facebook 
or Blog comments), but its reach is limited to those 
who already follow one of the accounts which posts or 
re-tweets the invitations. It provided an excellent oppor-
tunity to draw in active PPI parent volunteers, but did not 
attract a large number of young people. Directly adver-
tising the opportunity to be involved in the work to young 
people via other groups, such as Young People’s Advisory 
Groups hosted by organisations such as the National 
Cancer Research Institute or Clic-Sergant, or advertising 
through the Teenage Cancer Trust, may have resulted in 
more than one young person getting involved.
The findings of this study have immediately influ-
enced an application for a feasibility study of procal-
citonin-guided management of FN. They will also 
influence the ongoing development of clinical practice 
by dissemination through children’s and young people’s 
professional network groups. The participants in this 
group have expressed a wish to be a part of the steering 
committee of a trial addressing this issue, and the ongoing 
study development will also seek further involvement of 
young people, following INVOLVE guidelines.17 18 One 
of the group members has joined the study as a co-appli-
cant, developing the grant and plans to be involved as a 
co-investigator.
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box 2 Changes following consultation
 Ź Individual patient randomised trial (randomising by patient, not by 
episode).
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